List of Stem Cells Companies in Switzerland - 12

Cellestia Biotech is pioneering innovative therapeutics based on novel modes of action to treat autoimmune diseases and multi-drug resistant cancers. Our clinical stage drug candidate, CB-103, has demonstrated both safety and biological activity in humans. Along with ongoing Phase 2 IITs for multi-drug resistant cancers, CB-103 is also poised to enter a Proof-of-Concept clinical study for graft-versus-host disease (GvHD)

Cimeio Therapeutics is an applied gene editing, cellular, and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs for patients with serious and life-threatening diseases. Cimeio’s proprietary technology platform is based on the discovery of protein variants, which when edited into cells allow them to maintain full function while resisting paired immunotherapy depletion. This technology has significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with genetic diseases, hematologic malignancies, and severe autoimmune disorders.

DiNAQOR is a genetic medicine platform company pioneering early-stage drug development and manufacturing to advance promising gene therapies to the clinic. Our patent-protected, industry leading platform is designed to overcome the challenges and limitations of advanced gene therapy development by using proprietary engineered heart tissue technology (EHT), a novel Loco-Regional Perfusion system (LRP) and a fully integrated manufacturing solution. Our company is headquartered in the Greater Zurich Area, Switzerland, with additional presence in Laguna Hills, California and Hamburg, Germany.

endogena’s mission is to discover and develop first-in-class endogenous regenerative medicines to repair and regenerate tissues and organs. our approach has the potential for a medical treatment paradigm change to effectively address unmet medical needs associated with ageing and genetic diseases. endogena therapeutics is implementing state-of-the art innovation in the field of regenerative medicine. our science combines the latest developments in stem cell biology, artificial intelligence and our expertise in small-molecule drug design to develop breakthrough treatments for degenerative diseases. recent breakthroughs in stem cell biology together with technological advances for phenotypic, functional screening have unlocked our ability to harness the potential of adult stem- and precursor cells. our novel drug discovery approach is based on the concept of selective activation of endogenous progenitor cells for controlled tissue repair and regeneration by small molecules.

Exogems uses an FDA-approved medical device (Lipogems®) to produce exosomes from the mesenchymal stems cells in fat. They are developing methods for using these exosomes to deliver therapeutics.

HemostOD is a biotech company based at the EPFL Innovation Park in Lausanne, Switzerland. They are a preclinical stage company developing a therapeutic platform inspired by platelet biology.

Limula offers a unique technology supporting routine manufacturing of highly-personalised cell therapies. They provide a modular solution for on-demand cell and gene therapy manufacturing, addressing one of the biggest challenges in the field of medicine.

MPC Therapeutics is a biotechnology company focused on cellular rejuvenation to fight cancer & degenerative pathologies. They develop a class of compounds with applications in immunotherapy and metabolic diseases. The company is founded on the belief that they can manipulate cell behavior to fight cancer and degenerative diseases.

Neovii is a global leader in polyclonal antibody immunosuppressive therapy used in organ transplantation and hematology/oncology. Our lead product, Grafalon®, has been used for over 30 years to treat patients and is available in more than 40 countries world wide. It has approval for use in immunosuppressive therapies for prevention of graft- versus- host disease in stem cell transplantation, prevention and treatment of rejection in solid organ transplantation and in treatment of aplastic anemia.

To help get better and safer medicines to patients faster. We developed a robust technology and translated it into a unique product which today serves as the gold standard for in vitro testing of products and pharmaceuticals.

Somagenetix is a new company that aims at becoming a leading gene therapy company with first-in-class treatment for phagocyte-related disorders. We are spin-off from the University of Zurich and we are leveraging world-class scientific and clinical expertise to solve unmet medical needs through gene therapy. Carried by a highly experienced scientific team with over 17 years experience in gene therapy research, clinical development and applications, our mission is to cure all patients with Phagocyte Disorders. A cutting-edge technology with a complete & unique platform solving all challenges of ex-vivo gene therapies: specificity, long-term efficacy and safety. Our goal is to cure patients with immunodeficiency, neurodegeneration and cancer with brain metastasis via genetically enhanced phagocytes.